FeesSafety
Pluang+

Waters Corporation acquires MOBILion to boost proteomics with advanced ion mobility tech.

Company Fundamentals
03 Nov 2026, 12:55 WIB
PRNewsWire
View Source
Bullish
Waters Corporation acquires MOBILion to boost proteomics with advanced ion mobility tech.

Waters Corporation has acquired MOBILion Systems, a leader in SLIM high-resolution ion mobility technology, enhancing Waters' proteomics capabilities by combining SLIM with its Xevo™ MRT mass spectrometry platform. This acquisition improves molecular separation, enabling deeper proteome analysis and supporting AI-driven research workflows. It also paves the way for translating protein biomarker discoveries into clinical applications, including blood-based diagnostics for cancer detection and disease monitoring. The deal strengthens Waters' position in the growing $2 billion proteomics market and accelerates innovation from research to clinical use.

Waters Corporation's acquisition of MOBILion Systems is the subject, with Pluang's Health sector market data provided for context. As of Nov 03, 2026 16:31 WIB, 74 of 150 priced Health-sector US stocks rose while 64 fell. Among notable movers, CYTK (Cytokinetics Inc) rose 1.81% to USD 63.15, AHCO (AdaptHealth Corp) fell 1.95% to USD 5.79 with a 90% buy order activity, and DYN (Dyne Therapeutics Inc) dropped 2.54% to USD 16.86 with a typical hold time of 9 days on Pluang.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App